FDA 批准诺华的 Fabhalta 用于治疗 C3 肾小球病，这是一种罕见的肾脏疾病。 FDA approves Novartis' Fabhalta for C3 glomerulopathy, a rare kidney disease.

Novartis已经获得林业发展局对Fabhalta(Iptacopan)的核准,这是首次治疗C3球球病(C3G),一种罕见的肾病。 Novartis has received FDA approval for Fabhalta (iptacopan), the first treatment for C3 glomerulopathy (C3G), a rare kidney disorder. Fabhalta是一种口服药物,针对补充系统,在管理C3G方面显示出成效,减少了蛋白质并取得了良好的安全效果。 Fabhalta, an oral medication, targets the complement system and has shown effectiveness in managing C3G, reducing proteinuria with good safety outcomes. 这一批准为这种罕见病症的病人提供了新的希望,这种病症往往导致肾衰竭。 This approval offers new hope for patients with this rare condition, which often leads to kidney failure.